BioCentury
ARTICLE | Company News

Boehringer submits empagliflozin NDA

March 26, 2013 12:43 AM UTC

Boehringer Ingelheim GmbH (Ingelheim, Germany) submitted an NDA to FDA for empagliflozin to treat Type II diabetes. Boehringer, which is partnered with Eli Lilly and Co. (NYSE:LLY) to co-develop and c...